Blue Earth Therapeutics Expands Manufacturing Collaboration with Seibersdorf Labor
Blue Earth Therapeutics, a subsidiary of Bracco, has expanded its manufacturing partnership with Seibersdorf Labor GmbH to include the production of its investigational (225Ac) rhPSMA-10.1 radioligand therapy. This expansion complements existing agreements for the manufacture of (177Lu) rhPSMA-10.1.
(225Ac) rhPSMA-10.1 is a radiohybrid therapeutic radiopharmaceutical that targets Prostate-Specific Membrane Antigen (PSMA) on prostate cancer cells. It offers potential advantages in precision medicine for prostate cancer treatment.
Blue Earth Therapeutics’ CEO, David E. Gauden, emphasized the purity and stability of the (225Ac)-based product and the partnership’s ability to supply clinical trial sites in the UK, EU, and US.
Seibersdorf Labor’s Managing Director, Dr. Markus Neumann, highlighted the implementation of dedicated infrastructure to support the production of (225Ac) and their excitement about expanding their partnership with Blue Earth Therapeutics.
The expansion supports a recently announced research collaboration with University College London to progress a Phase 1/2 clinical trial of (225Ac) rhPSMA-10.1 in metastatic castrate-resistant prostate cancer.
Blue Earth Therapeutics’ rhPSMA compounds are based on technology originally developed at the Technical University of Munich. Blue Earth Diagnostics acquired worldwide rights to the technology in 2018 and 2020, and Blue Earth Therapeutics is currently conducting clinical trials of its rhPSMA compounds.
Blue Earth Therapeutics is committed to developing targeted radiotherapeutics for cancer patients, leveraging its expertise in radiopharmaceutical and oncology drug development.
Source link: http://www.businesswire.com/news/home/20240812462733/en/Blue-Earth-Therapeutics-Ltd-Announces-Expansion-of-Partnership-With-Seibersdorf-Labor-GmbH-to-Include-Manufacture-of-Therapeutic-Radiopharmaceutical-225Ac-rhPSMA-10.1
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
